AttendMe Owl Logo
AttendMe
Evidence Evolution
Hepatobiliary SurgeryHepatobiliary Surgery

How This Evidence Evolved

Portal Vein Embolization and ALPPS

Strategies to Augment Future Liver Remnant Volume for Extended Hepatic Resection

24.5

Timeline

Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

Makuuchi and colleagues reported preoperative portal vein embolization in 14 patients with hilar bile duct carcinoma in 1990. The aim was atrophy of the lobe to be resected and hypertrophy of the opposite lobe before major hepatectomy. At surgery 6–41 days later, the embolized lobe was atrophied in 12 patients. Embolization caused no major side-effects, but two patients died after subsequent surgery: one at 30 days with jaundice and suppurative cholangitis and one at 3 months from aggravated hepatitis.
Proof

Landmark RCTs and pivotal trials that established the evidence base

The 2012 ALPPS report described preoperative PVE as the established standard for achieving resectability. In a 2003 prospective trial, 55 patients with liver metastases, hepatocellular carcinoma or cholangiocarcinoma were alternately assigned to right hepatectomy after PVE (28) or immediate surgery (27). The mean FLR increase 4 to 8 weeks after PVE was 44% with normal liver and 35% with chronic liver disease. PVE gave no benefit in postoperative course with normal liver, but with chronic liver disease it significantly reduced postoperative complications and intensive care and hospital stay.
Extension

Follow-up studies, subgroup analyses, and real-world validation

The international ALPPS registry held more than 1,100 cases by May 2019; its first major report (202 procedures) showed Clavien-Dindo grade 3 or higher morbidity of 27% and mortality of 9%. In the first randomized trial, ALPPS gave a higher resectability rate than two-stage hepatectomy, with similar complication rates. Better patient selection and less invasive variants (partial, tourniquet, hybrid, laparoscopic or robotic ALPPS) significantly improved safety. Liver venous deprivation combines ipsilateral portal and hepatic vein branch embolization in the same procedure.
Guidelines

Integration into clinical practice guidelines and recommendations

CIRSE 2024 Standards of Practice recommends PVE first-line to induce FLR hypertrophy before major hepatectomy. It describes sequential hepatic vein embolization after PVE, LVD, DVE and ALPPS as proposed strategies for insufficient regeneration after PVE.
CIRSE Standards of Practice on PVE and DVE/LVD

PVE first-line before major hepatectomy; proposed strategies after insufficient PVE regeneration include sequential HVE, LVD, DVE and ALPPS.

CIRSE Standards of Practice on PVE and DVE/LVD

PVE is the first-line approach to induce FLR hypertrophy before major hepatectomy; suggested safe FLR/TLV >20% normal, >30% prior chemotherapy, >40% cirrhotic/cholestatic liver.

Now

Current standard of care and ongoing research directions

A 2012 report described PVE as the standard preoperative augmentation procedure. The ALPPS registry review reports improved safety with refined selection and techniques. A 2024 meta-analysis of 10 studies (588 patients) compared LVD with PVE: resection was more likely with LVD (OR 1.89, 95% CI 1.13–3.15), but 90-day mortality did not differ significantly (OR 0.38, 95% CI 0.13–1.09). It did not compare LVD with ALPPS.

Landmark Trials in This Story

Makuuchi PVE1990Landmark

Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report

Embolized-lobe atrophy at hepatectomy, 6-41 days after embolization: 12/14; no major embolization side effects; 2 later postoperative deaths

SurgeryCohortN=14
Farges PVE Trial2003

Portal vein embolization before right hepatectomy: prospective clinical trial.

Mean FLR increase 4-8 weeks after PVE: normal liver 44% ± 19% vs chronic liver disease 35% ± 28%

Ann SurgProspective clinical trial; consecutive patients alternately assigned to right hepatectomy after PVE (28) or immediate surgery (27)N=55
ALPPS Registry2020Landmark

Associated Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Registry: What Have We Learned?

Clavien-Dindo grade 3 or higher morbidity and mortality, first registry report (202 procedures): 27% and 9% (single arm)

Gut and liverReview
Schnitzbauer ALPPS Series2012

Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.

Left lateral lobe volume increase at a median 9 days (range 5-28) after step 1: median 74% (range 21%-192%; P < 0.001)

Ann SurgCase series; two-stage hepatectomy with right portal vein ligation and in situ liver splitting in marginally resectable liver tumorsN=25
LVD versus PVE meta-analysis2024

Comparison of liver venous deprivation with portal vein embolization alone in patients undergoing major liver resection: a systematic review and meta-analysis.

LVD vs PVE: resection OR 1.89 (95% CI 1.13–3.15); 90-day mortality OR 0.38 (95% CI 0.13–1.09), not significant

HPB : the official journal of the International Hepato Pancreato Biliary AssociationSystematic review and meta-analysis of 10 comparative studiesN=588

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

What is the difference between PVE and ALPPS?+
Portal vein embolization (PVE), reported by Makuuchi in 1990, embolizes the portal branch supplying the liver to be resected, so this lobe atrophies and the other hypertrophies; in a 2003 prospective trial the FLR grew by a mean 44% (normal liver) or 35% (chronic liver disease) 4 to 8 weeks after PVE. In the first randomized trial, ALPPS gave higher resectability than two-stage hepatectomy with similar complication rates. How best to use ALPPS is still debated.
When is FLR augmentation necessary?+
PVE is usually indicated when the FLR is too small for major liver resection. CIRSE 2024 lists suggested safe FLR/total-liver-volume ratios >20% for normal liver, >30% after chemotherapy, and >40% for cirrhotic or cholestatic liver. Volume assessment does not fully measure liver function. Extensive resection for hilar bile duct carcinoma with jaundice risks postoperative liver failure (Makuuchi 1990).

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026